The vasomotor symptoms (VMS) market includes products that help alleviate symptoms associated with hormonal fluctuations during menopause, such as hot flashes and night sweats. With rising frequency and intensity of hot flashes, many women look for safe and effective treatment options to manage vasomotor symptoms. Hormone therapy remains the most effective therapy, however, non-hormonal options like antidepressants and herbal supplements are increasingly preferred due to potential health risks linked with hormones.
The Vasomotor Symptoms Market is estimated to be valued at USD 3.71 billion in 2024 and is expected to reach USD 6.40 billion by 2031, growing at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Key players operating in the vasomotor symptoms market are Pfizer, Novartis, Novo Nordisk, and AbbVie. Growing awareness about alternative therapies and recent pipeline product approvals are creating high growth opportunities in non-hormonal therapy segments in developing countries. Leading companies are expanding their geographic footprint in Asia Pacific and Latin America through partnerships with local generic manufacturers to tap the rising demand from aging population in these regions.
Market Drivers
The rising prevalence of menopause owing to increasing life expectancy is a major Vasomotor Symptoms Market driver. According to the National Institute on Aging, over 52 million American women are currently going through menopause or have gone through menopause. A growing aging female population base globally is anticipated to fuel demand for effective treatment over the forecast period.
Market Restrains
Stringent regulatory guidelines for approval of drugs related to women's health and reproductive system is a key challenge for market players. High development cost and risk of failure associated with hormonal therapy also restrains market growth to some extent.
Segment Analysis
The global vasomotor symptoms market is segmented by type and end user. Based on type, hot flashes/flushes segment dominated the market in 2020 as it is the most common symptom experienced by women during menopause transition. Around 75% of women experience hot flashes during menopause and hot flashes can occur frequently throughout the day. Based on end user, hospitals segment accounted for the largest share in 2020. Hospitals offer advanced treatment options and have all necessary infrastructure & facilities to effectively treat and manage menopause related symptoms like hot flashes.
Global Analysis
Regionally, North America dominated the global vasomotor symptoms market in 2020 attributed to increasing menopausal population and availability of advanced treatment options. According to the North American Menopause Society, around 2.5 million American women experience menopause each year. Asia Pacific is expected to witness highest growth during the forecast period owing to rising healthcare expenditure, growing awareness about treatment of menopause symptoms, and improving healthcare infrastructure. Countries like China and Japan have large aging population experiencing menopause symptoms providing significant growth opportunities.
Get this Report in Japanese Language: 血管運動症状市場
Get this Report in Korean Language: 혈관 운동 증상 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
